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Worldwide, more individuals have iron deficiency than any other health problem. Most of
those affected are unaware of their lack of iron, in part because detection of iron deficiency
has required a blood sample. Here we report a non-invasive method to optically measure an
established indicator of iron status, red blood cell zinc protoporphyrin, in the microcirculation
of the lower lip. An optical fibre probe is used to illuminate the lip and acquire fluorescence
emission spectra in B1 min. Dual-wavelength excitation with spectral fitting is used to dis-
tinguish the faint zinc protoporphyrin fluorescence from the much greater tissue background
fluorescence, providing immediate results. In 56 women, 35 of whom were iron-deficient, the
sensitivity and specificity of optical non-invasive detection of iron deficiency were 97% and
90%, respectively. This fluorescence method potentially provides a rapid, easy to use means
for point-of-care screening for iron deficiency in resource-limited settings lacking laboratory
infrastructure.
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W
orldwide, iron deficiency affects more individuals
than any other health problem1. Lack of iron
causes anaemia2, impairs cognitive and behavioural
development in childhood3,4, compromises immune
responsiveness5, diminishes physical performance6 and, when
severe, increases mortality among infants, children and pregnant
women4,7. Effective and inexpensive treatment is available3, but
most of those affected are unaware of their need for more iron.
Detection of iron deficiency, with a requirement for a blood
sample and some forms of laboratory processing8, has been
generally unavailable in the same resource-limited settings where
a lack of iron is most common9.
We report an optical method to detect iron deficiency without
the need for a blood sample. In the developing red blood cell, the
insertion of iron into protoporphyrin IX is the final step in the
production of haem for incorporation into haemoglobin10. If iron
is unavailable, divalent zinc is incorporated instead, producing
zinc protoporphyrin, which persists for the life of the red blood
cell as a biochemical indicator of functional iron deficiency11,12.
In regions endemic for malaria and other infections, the
World Health Organization recommends measurement of the
red blood cell zinc protoporphyrin as the preferred indicator to
screen children for iron deficiency13. In the United States, the
American Academy of Pediatrics recommends universal
screening for iron deficiency at 1 year of age14, and the use of
red blood cell zinc protoporphyrin for this purpose has been
suggested15. Screening for iron deficiency using red blood cell
zinc protoporphyrin meets the classical criteria defined by Wilson
and Jungner16 as well as more recently proposed standards17.
Non-invasive screening is likely to be more acceptable to children
and many other populations than methods requiring finger- or
venipuncture.
With blue light excitation, zinc protoporphyrin fluoresces,
while haem does not. To detect this faint fluorescence, we use an
optical fibre probe to illuminate and acquire the fluorescence
emission spectra from the lower lip, where only a thin, non-
pigmented epithelial layer covers the blood-filled capillaries
perfusing the underlying tissue. Still, this mucosal tissue contains
collagen, elastin and other fluorophores that produce a back-
ground fluorescence whose intensity is two orders of magnitude
greater than that from red blood cell zinc protoporphyrin. We use
dual-wavelength excitation and spectral fitting to distinguish the
faint zinc protoporphyrin fluorescence from the mucosal tissue
background. Spectral analysis is also used to identify tissue sites
suitable for quantitative fluorescence measurements. Here we
describe the integration of these technical innovations in portable,
point-of-care instrumentation to quantify red blood cell zinc
protoporphyrin fluorescence from the lower lip. Measurements
use only light and subjects have no electrical exposure. Using the
portable instrument, we sought to compare the results of
fluorescence measurements in vivo in women shortly after
childbirth with determinations on blood samples in vitro by a
standard reference method using high-performance liquid
chromatography (HPLC), and by a conventional haematofluo-
rometer that measures red blood cell zinc protoporphyrin
fluorescence directly from a blood sample. Optical measurements
in the lower lip in these women have a sensitivity of 97% and a
specificity of 90% for iron deficiency. Overall, our results provide
proof-of-concept validation for non-invasive detection of iron
deficiency by optical fibre probe fluorescence spectroscopy of the
lower lip.
Results
In brief, to measure non-invasively the red blood cell zinc
protoporphyrin, we place the optical fibre probe in gentle contact
with the red vermillion of the lower lip of the subject and slowly
move the probe over the surface (Fig. 1a,b). Suitable sites for
measurement of the red blood cell zinc protoporphyrin are
detected in real time by determination of the ‘blood absorption
index’ and indicated to the examiner by illumination of an light-
emitting diode (LED) indicator attached to the optical fibre probe
(Fig. 1b). The blood absorption index, detailed below, identifies
sites on the lower lip where mucosal tissue properties (including
haemoglobin concentration, light scattering coefficient, blood
vessel size and epithelial thickness) permit quantitative measure-
ment of red blood cell zinc protoporphyrin. While the blood
absorption index identifies suitable sites for measurement, the
index does not enter into the calculation. Instead, dual-
wavelength excitation and spectral fitting are then used at a
suitable site to quantitatively determine zinc protoporphyrin.
In presenting our results below, we first describe the dual-
wavelength and spectral fitting procedures and then detail how
the blood absorption index can identify suitable tissue sites for
quantitative measurements.
Measurement of erythrocyte zinc protoporphyrin fluorescence.
To detect the faint fluorescence of red blood cell zinc proto-
porphyrin, we use an optical fibre probe to illuminate and acquire
the fluorescence emission spectra from the blood-filled capillaries
beneath the wet vermillion of the lower lip (Fig. 1a,b; see
Supplementary Figs 1 and 2 for a detailed schematic and a
photograph of the instrument with the optical fibre probe). At the
wavelength of maximum red blood cell zinc protoporphyrin
fluorescence excitation, 425 nm, collagen, elastin and other tissue
fluorophores emit background fluorescence with an intensity a
hundredfold greater than that from red blood cell zinc proto-
porphyrin18. To quantitatively extract the zinc protoporphyrin
fluorescence in the presence of this very large background, we
acquire additional fluorescence spectra excited at a wavelength of
407 nm (ref. 19). Both spectra are obtained with an excitation
power of B2.5 mW for the illuminated area of 1-mm diameter to
comply with the light-exposure limits defined by the international
standard IEC 60825-1:2014. At the 425- and 407-nm excitation
wavelengths, the light absorption of capillary blood is virtually
identical and, under the conditions of our measurements, little
influenced by tissue properties (Fig. 1c; see Supplementary Note 1
for details of the choice of the excitation wavelengths and the
influence of tissue properties). Because structures in the tissue
absorption spectrum are dominated by capillary blood in this
wavelength region and light scattering is nearly identical20, both
wavelengths probe approximately the same tissue volume,
producing similar background fluorescence spectra (Fig. 1d).
Since the excitation efficiency of red blood cell zinc
protoporphyrin is B78% lower at the 407-nm excitation
wavelength compared with that at 425 nm (Fig. 1c), the
difference spectrum retains most of the zinc protoporphyrin
fluorescence while reducing the fluorescence background at
593 nm by 93±2% (s.d.; Fig. 1e). At 407 nm, protoporphyrin
IX fluorescence excitation is greater than that at 425 nm,
producing a negative contribution to the difference spectrum.
To extract the zinc protoporphyrin fluorescence contribution
from the difference spectrum, a spectral fitting algorithm is
applied (Fig. 2). Because the spectral shape of the fluorescence
background varies from subject to subject and in different areas
on the lower lip within the same subject, fully modelling the
difference spectrum proved impractical. We use an alternative
approach based on calculating the second derivative of the
difference spectrum21. This procedure is insensitive to the
background fluorescence spectrum, which lacks characteristic
structures. Inputs for the fitting algorithm are the blood
absorption spectrum and the zinc protoporphyrin and
protoporphyrin IX fluorescence spectra (see Supplementary
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Figs 3 and 4 for detailed spectra). The output parameters are the
amplitudes of the zinc protoporphyrin and protoporphyrin IX
fluorescence spectra and of the blood absorption spectrum.
Identification of suitable measurement sites. The molar ratio of
zinc protoporphyrin to haem, or mmol zinc protoporphyrin
per mol haem, is the preferred unit for measurement of
red blood cell zinc protoporphyrin22. With the conventional
haematofluorometer, the amplitude of the red blood cell zinc
protoporphyrin fluorescence is proportional to the molar ratio of
the concentration of zinc protoporphyrin to the concentration
of haemoglobin rather than to the concentration of zinc
protoporphyrin alone23 (see Supplementary Note 1 for
derivation). Similarly, under the conditions of our fibre-based
measurements, the detected zinc protoporphyrin fluorescence is
proportional to the zinc protoporphyrin/haem ratio and, over a
wide range (Fig. 3a), nearly independent of the red blood cell
concentration. In our measurements of the wet vermillion of the
lower lip, the proportionality of zinc protoporphyrin fluorescence
to the zinc protoporphyrin/haem ratio is preserved at sites
that can be identified in real time by the magnitude of the
decrease in the tissue background fluorescence spectrum resulting
from blood absorption (Fig. 3b), termed hereafter the tissue
‘blood absorption index’.
For a constant zinc protoporphyrin/haem ratio, Monte Carlo
simulations indicated that deviations of the detected zinc
protoporphyrin fluorescence are found for variations in epithelial
thickness, in light scattering coefficient, in the amount of blood
present in the tissue volume, termed the tissue blood volume
fraction, and in the average blood vessel diameter (Supplementary
Fig. 5a–d for Monte Carlo simulation results). The influence of
light scattering is virtually eliminated for a broad range of
possible tissue parameters by the appropriate choice of the
diameter of the excitation and detection fibre, in our case
1,000 mm (Supplementary Fig. 5c), which also leads to a high
amount of detected fluorescence photons (Supplementary Fig. 5e;
see Supplementary Note 1 for details about the choice of the fibre
diameter). For other mucosal tissue properties, including the red
blood cell concentration, the blood volume fraction, the mean
blood vessel diameter, epithelial thickness and other factors, we
found that the blood absorption index (Fig. 3b) correlates with
the deviation of the detected zinc protoporphyrin fluorescence
in vivo from reference HPLC measurements in vitro. A
comparison of tissue fluorescence measurements on 14 subjects
in a preparatory study with the corresponding HPLC determina-
tions is shown in Fig. 3c (see also Supplementary Fig. 6a,b for a
comparison with Monte Carlo simulations). In non-invasive
measurements, the blood absorption index is used to prospec-
tively identify suitable tissue sites for quantitative measurements,
that is, those sites where only minor deviations of the detected
zinc protoporphyrin fluorescence from reference HPLC values are
expected. In our instrument, we determine the blood absorption
index in real time. Active feedback in the form of a series of LED
indicators (black box in Fig. 1b) is given to the examiner as the
fibre-optic probe is moved over the lower lip. When the fibre-
optic probe reaches an area with a blood absorption index above
the pre-defined value (Fig. 3c), the examiner can activate the
measurement process. Measurements were begun in the clinical
study reported here only when the blood absorption index
exceeded the lower threshold of 0.7 10 2. To maintain stable







































































Figure 1 | Tissue fluorescence measurements using dual-wavelength excitation. (a) Simplified schematic of the set-up. Light of two laser diodes at 407
and 425 nm is superimposed and coupled into an optical fibre for fluorescence excitation. The generated fluorescence is collected by the same fibre and
detected with a spectrometer. (b) Photograph of the measurement procedure with the fibre-optic probe placed on the lower lip. An adequate blood
absorption index is indicated by the green light on the black indicator box. (c) The fluorescence excitation maximum of red blood cell zinc protoporphyrin
(ZnPP) is at 425 nm. The second excitation wavelength of 407 nm is chosen for identical blood absorption. (d) Typical fluorescence spectra of the oral
mucosa of a single subject with elevated ZnPP/haem ratio when excited with 425 and 407 nm. (e) Difference spectrum of the spectra in d with normalized
407-nm spectrum, resulting in background reduction of B93%. The corresponding difference spectrum of a measurement in whole blood using the same
instrumentation in vitro is shown in red, obtained by placing the optical fibre in a sample of whole blood.
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tissue perfusion during the measurement, the 1,000-mm fibre is
embedded into a 12-mm steel ferrule (see Supplementary Fig. 2b
for a photograph), reducing the pressure of the probe on the
tissue.
Evaluation in women after childbirth. The performance of the
non-invasive method for detection of iron deficiency was
evaluated in a clinical study of 56 women within 3 days after
childbirth. The mean haemoglobin concentration after delivery
was 10.9 g dl 1 (range: 6.7–15.8 g dl 1). The correlation between
the averaged non-invasive measurements in vivo and the mean
of triplicate reference HPLC measurements in vitro is shown
in Fig. 4a (Spearman’s rho rs¼ 0.87). The robust limits of
agreement between the non-invasive and reference HPLC mea-
surements, shown in the Bland–Altman plot in Fig. 4b,
were 19 mmol per mol haem (95% confidence interval (CI):
14–24 mmol per mol haem, bias:  1 mmol per mol haem). For
comparison, the robust limits of agreement between separate
determinations by the HPLC method were 16 mmol per mol haem
(95% CI: 13–19mmol per mol haem, bias: 4mmol per mol haem; see
Supplementary Fig. 7 for the correlation and a Bland–Altman plot).
We used the HPLC measurements to classify subjects as
functionally iron-deficient (zinc protoporphyrin450mmol mol 1
haem) or as iron-replete or indeterminate (zinc protoporphyrin
r50 mmol per mol haem; Fig. 4). For the non-invasive method,
the sensitivity for detection of iron deficiency was 97% (95% CI:
87–100%) with a specificity of 90% (95% CI: 73–98%), positive
predictive value of 94% (95% CI: 85–98%) and a negative
predictive value of 95% (95% CI: 79–99%).
The precision of the non-invasive measurements, determined as
the s.e.m. from the 100 zinc protoporphyrin amplitudes measured
for each subject, was 1.9mmol per mol haem (range: 1.1–2.9mmol
per mol haem, see Supplementary Fig. 8 for the distribution).
Interexaminer variability was studied by five examiners who were
trained in use of the optical fibre for 5 min. Then, each examiner
conducted measurements on the same subject. The s.d. of the
average zinc protoporphyrin values was 4mmol per mol haem for
these five examiners. The repeatability of the non-invasive tissue
measurements was evaluated by comparing the average over the
first 50 zinc protoporphyrin amplitudes acquired from five
different tissue locations, with the last 50 from the other five
tissue locations for all 56 subjects. The limits of agreement of the
difference of the corresponding average values were 15mmol per
mol haem (1.96 s.d.).
Following the usual practice in field studies, unwashed whole-
blood samples from the 56 subjects were also measured using a
conventional haematofluorometer. We used receiver operating
characteristic analysis to determine an optimal threshold of
4115 mmol per mol haem to classify subjects as functionally iron-
deficient according to the HPLC results. The corresponding
sensitivity for detection of iron deficiency was 89% (95% CI:
76–96%), with a specificity of 90% (95% CI: 73–98%), positive
predictive value of 94% (95% CI: 84–98%) and a negative
predictive value of 83% (95% CI: 68–91%).
Discussion
These results provide proof-of-concept validation for non-
invasive detection of iron deficiency by optical fibre probe






























































Figure 2 | Spectral fitting procedure to separate the ZnPP and protoporphyrin IX (PPIX) fluorescence from background. (a) Averaged difference
spectrum of 100 single spectra measured in the same subject as for Fig. 1e, and the input spectra of ZnPP, PPIX and blood absorption that are used for the
fitting procedure. (b) Second derivatives of the tissue difference spectrum shown in a, and of the fitted components. (c) Difference spectrum and the
smooth background that remains when ZnPP, PPIX and blood absorption are removed according to the obtained fit amplitudes, indicating the effectiveness
and validity of the spectral fitting procedure.


































































Figure 3 | Using the blood absorption index to identify suitable tissue sites for quantitative measurement of the ZnPP/haem ratio. (a) For whole-blood
concentrations between 2 and 8% (whole blood of a healthy subject diluted by saline), the measured ZnPP fluorescence remains little changed despite this
large variation in the blood concentration. (b) Illustration of the blood absorption index. The magnitude of the decrease in the tissue-background
fluorescence spectrum resulting from blood absorption, termed the ‘blood absorption index’, is continuously analysed during the measurement by
evaluating three spectral bands centred at 562, 576 and 593 nm, around a blood absorption peak. (c) The blood absorption index in relation to the relative
deviation of the measured values in vivo from HPLC reference values in vitro. Data from 10 measurement sites from each of 14 subjects are shown. To guide
the examiner to a site on the lower lip with an adequate blood absorption index, feedback by an indicator light is given as red, red-orange, orange and green.
Measurements are only started at sites with a blood absorption index 40.7 10 2 (green) to ensure that the relationship between the detected
red blood cell ZnPP fluorescence and the ZnPP/haem ratio is preserved.
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fluorescence spectroscopy of the lower lip. Close quantitative
agreement was found between the results of measurements of red
blood cell zinc protoporphyrin by the fluorescence method in vivo
and by a standard HPLC reference assay in blood samples in vitro
(Fig. 4a,b). In this population of women examined shortly after
childbirth, the optical measurements in the lower lip had a
sensitivity of 97% and a specificity of 90% for iron deficiency
(Fig. 4a), using zinc protoporphyrin/haem ratios 450mmol per
mol haem as determined by HPLC as the criterion for functional
iron deficiency. These fluorescence measurements were made
possible by the integration of three technical innovations in the
portable instrumentation reported here. First, spectral analysis of
the effect of haem absorption on the tissue background
fluorescence spectrum identifies suitable tissue sites, with a
sufficiently thin epithelial layer and an adequate amount of blood
in the tissue volume examined (Fig. 3). Second, the dual-
wavelength excitation method reduces the contribution of the
background fluorescence in the difference spectrum by more than
90% (Fig. 1d,e). Third, spectral fitting extracts the zinc
protoporphyrin component from the difference spectrum
(Fig. 2). The combination of these elements in the device
reported here makes possible quantitation of red blood cell zinc
protoporphyrin/haem ratio in the tissue of the lower lip in vivo
with a precision approaching that of the standard reference HPLC
method in a blood sample in vitro. The limits of agreement of
19 mmol per mol haem for the comparison of the non-invasive
measurements with HPLC are close to those of 16 mmol per mol
haem for the comparison of the samples that were measured on
two occasions by HPLC.
Remarkably, the sensitivity and specificity of our non-invasive
technique are at least comparable to those of a conventional
haematofluorometer (sensitivity of 89% and specificity of 90%)
using a drop of unwashed whole blood, as is usually done
under field conditions. Washing the red blood cells is known to
improve the precision of measurements by the conventional
haematofluorometer24, but requires additional laboratory
facilities and trained personnel. As shown in a previous study,
the dual-wavelength excitation method effectively reduces plasma
bilirubin fluorescence19. The spectral fitting algorithm, by
eliminating unstructured background fluorescence in the
difference spectrum, likely suppresses interference from
medications and other components in the plasma or bound to
erythrocyte membranes, but this effect has not been
systematically examined.
As yet, we have examined the non-invasive method only in
adult women. We plan to extend our studies to adult men and
also to children. The conditions of measurements in children are
likely to be favourable physiologically, with a thinner epithelium
and abundant vasculature. While perioral pigmentation of the wet
vermillion of the lower lip is uncommon25,26 and no interference
with the non-invasive measurements was found in six subjects
with dark skin pigmentation included in our series, we have not
yet determined whether measures to detect and correct for the
presence of melanin are needed.
Red blood cell zinc protoporphyrin is an established indicator
of iron deficiency11,27 that has been used clinically for almost
50 years (refs 15,28,29) and has been included in the periodic
US National Health and Nutrition Examination Surveys30.
Red blood cell zinc protoporphyrin provides a measure of
functional iron deficiency, when a decreased supply of iron
restricts production of haemoglobin and other iron-requiring
compounds31. Worldwide, iron deficiency, with the iron supply
restricted by an insufficient amount of iron in the body, is the
principal cause of an elevated red blood cell zinc protoporphyrin.
All biomarkers for iron deficiency are affected by malaria, by the
inflammatory response to infection, or both, and may be
influenced by conditions other than iron deficiency31,32. Red
blood cell zinc protoporphyrin is more stable than other
screening tests for iron deficiency, such as serum ferritin, that
can fluctuate within hours. In contrast, the amount of zinc
protoporphyrin in the peripheral blood changes only slowly as
newly formed red blood cells replace those at the end of their
lifespan of B3–4 months. In regions endemic for malaria and
other infections, the World Health Organization recommends red
blood cell zinc protoporphyrin as the preferred indicator of iron
deficiency in children13. Increases in red blood cell zinc
protoporphyrin also may be produced by conditions other than
iron deficiency. These disorders include lead or other heavy metal
exposure33,34, some haemoglobinopathies35–39 and a variety of
uncommon or rare genetic and acquired disorders, including
certain porphyrias40 and a variety of sideroblastic and inherited
microcytic anaemias41. Generally, these conditions are not a
barrier to the use of red blood cell zinc protoporphyrin to screen
for iron deficiency, but the procedures used will need to take
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Figure 4 | Comparison of the non-invasive measurements with the reference HPLC method in the clinical study of 56 women after childbirth.
(a) Comparison of the scaled non-invasive measurements in vivo with reference HPLC measurements in vitro. The blue area indicates values for
subjects who are iron-replete (red blood cell ZnPPo40mmol per mol haem) or in an indeterminate zone (red blood cell ZnPP 40–50mmol per mol haem,
in which elevations do not necessarily indicate iron deficiency but may result from recent infection, inflammation or other factors). The red-shaded area
indicates those who are functionally iron-deficient (red blood cell ZnPP450mmol per mol haem). The line of identity is shown by the diagonal line in red.
(b) Bland–Altman plot of the data presented in a. The blue lines indicate the robust limits of agreement (equalling 1.96 times the robust s.d.). The bias is
indicated by the dashed blue line. Details for the two outliers are provided in the Supplementary Note 2.
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account of their prevalence in the specific population examined
(see Supplementary Note 3 for a more detailed description of
these conditions). In clinical care, referral to a physician for
further evaluation may be necessary32.
The ultimate goal of this research is to engineer the
instrumentation for reliable, virtually maintenance-free field
operation. The principal component groups of the instrument
consist of a light source for dual-wavelength excitation, an optical
fibre probe head, a detection unit and electronics with display of
results. While the proof-of-concept device reported here was
assembled using commercially available parts, custom-made
components could substantially reduce device size and weight.
The most expensive component in the current instrument is the
spectrometer. The extent by which instrumental cost could be
reduced by use of less expensive photodetectors with sufficient
dynamic range and spectral resolution remains to be determined.
A specifically designed electronics board with a programmable
microprocessor and touch panel user interface could replace the
computer and the separate control electronics. Given the low-
power consumption (18 W), conversion to battery operation is
straightforward. With a housing specifically designed to accom-
modate the optics, beam steering components and electronics, we
anticipate that the instrument could be configured as a robust,
inexpensive unit with the dimensions of a paperback book and a
weight less than 0.5 kg. This fluorescence method potentially
provides a rapid, easy to use means for point-of-care screening for
iron deficiency in resource-limited settings lacking laboratory
infrastructure. More generally, dual-wavelength excitation with
spectral fitting is potentially useful in quantifying other blood-
bound fluorophores, especially in studies of the pharmacokinetics
of photosensitizers in photodynamic applications.
Methods
Non-invasive fluorescence measurements. For fluorescence measurements,
subjects sat in front of the examiner, gently turning the lower lip outwards. The
examiner placed the fibre-optic probe on the wet vermillion of the subject and
switched on the ‘search mode’ using a foot-switch. In this mode, fluorescence
spectra were acquired continuously with an integration time of 200 ms on 407-nm
excitation and analysed for the absorption caused by blood at its absorption
maximum B576 nm (Fig. 3b). The blood absorption index a was determined such
that the decrease in the tissue-background fluorescence around 576 nm could be
removed by dividing the tissue fluorescence spectrum by emaa where ma is the
blood absorption. If the blood absorption index exceeded the pre-defined value of
0.70 10 2 (Fig. 3c), a green light was illuminated, indicating to the examiner that
the current position on the lower lip was suitable for a reliable red blood cell zinc
protoporphyrin determination. For a blood absorption index between 0.42 10 2
and 0.70 10 2, a orange light was shown; between 0.14 10 2 and
0.42 10 2, red and orange lights; and below 0.14 10 2, a red light. The
examiner moved the fibre-optic probe slowly over the vermillion of the subject
until a green light was displayed, typically in B2–3 s. Then, the examiner began the
measurement procedure by using a foot-switch.
During the measurement procedure, the 407- and the 425-nm excitation laser
diodes were subsequently switched on and the resulting tissue fluorescence spectra
were acquired with a 200-ms integration time. To exclude marked variations in
tissue optical properties during this integration time, additional remission
measurements were carried out at the excitation wavelengths and with a 520-nm
laser diode using the surrounding fibres in the fibre bundle (Supplementary
Fig. 2b). The fibre bundle was attached to a photodiode that was read out with
2,000 samples at a rate of 10 kHz. No marked variations were found, and these
remission measurements do not enter into the calculation. Finally, all laser diodes
were switched off, and a dark spectrum and the photodiode dark signal were
collected with the above settings. This measurement cycle (successively switching
the three laser diodes on, finally switching all laser diodes off) was repeated
10 times, with a total duration of 10 s. All spectra and photodiode samples were
stored electronically.
During the 10-s measurement procedure, the examiner held the fibre-optic
probe in place at the tissue site. Afterwards, the examiner decided whether the
measurement at this site had been conducted under controlled circumstances, that
is, that the subject did not move and the fibre-optic probe did not lose contact to
the tissue during the measurement. In that case, the measurement was considered
valid. The procedure of starting the search mode, identifying a suitable
measurement site, starting the measurement and then deciding whether the
measurement was carried out under controlled conditions, was repeated until
10 valid measurements per patient had been conducted. Generally, no
measurement had to be excluded (on average 0.2 measurements were excluded
per subject, range 0–2, with a total of 12 invalid and 560 valid measurements).
Typically, the whole measurement procedure took less than 5 min. The total net
measurement time was B100 s (10 times 10 s).
Tissue data evaluation and spectral fitting. The acquired tissue fluorescence
spectra were evaluated using MATLAB (version R2013a, The MathWorks Inc.,
Natick, MA, USA). After the measurement for each subject, totals of 100 spectra
excited at 425 nm, Fitissue;425 lð Þ, 100 excited at 407 nm, Fitissue;407 lð Þ and 100 dark
spectra Fitissue;dark lð Þ were available. First, from each fluorescence spectrum, the
corresponding dark spectrum was subtracted. Then, the resulting spectrum was
divided by the integration time, 200 ms, normalizing the spectra to 1 ms, yielding
100 calibrated tissue spectra for each excitation wavelength, Fitissue;425;cal lð Þ and
F itissue;407;cal lð Þ. ‘Difference spectra’ Fitissue;D;cal lð Þ were calculated from the calibrated
fluorescence spectra by normalizing F itissue;407;cal lð Þ to Fitissue;425;cal lð Þ in the
wavelength range 520–525 nm and subsequent subtraction. In these difference
spectra, spectral features of blood absorption Ablood(l) (Supplementary Fig. 3), zinc
protoporphyrin fluorescence FZnPP(l) and protoporphyrin IX fluorescence FPPIX(l)
(Supplementary Fig. 4) are present (Fig. 2a). These spectral features were removed
from the difference spectra F itissue;D;cal lð Þ by optimizing the fit parameters a, z and p
so that the remaining fluorescence background was smooth in the wavelength
range 560–750 nm (Fig. 2c). This is the case when the second derivative of the
background with spectral features removed is as close to zero as possible (Fig. 2b).
This procedure is illustrated by the following equation:
d2
dl2
Fitissue;D;cal lð Þ=exp Ablood lð ÞaiD
 
 FZnPP lð ÞziD þ FPPIX lð ÞpiD
h i
! 0
Finally, the zinc protoporphyrin value for each subject was calculated by averaging
over the 100 ziD measured for each subject. These values are given in
Supplementary Table 1.
HPLC. HPLC was performed at the Deutsches Kompetenz-Zentrum für
Porphyriediagnostik und Konsultation, MVZ Labor PD Dr. Volkmann und
Kollegen GbR, Karlsruhe, Germany, using a system consisting of a Waters
autosampler 717 with pump 515, and a Shimadzu RF 20-AL detector. A Knauer
Nucleosil C18 column (250 4.6 mm, solvent 56% acetone, 24% methanol,
20% water and 0.02% formic acid (v/v/v)) was operated with a flow rate of
2.0 ml min 1. Fluorescence was excited at 417 nm and detected at 635 nm (20 nm
spectral bandwidth). A calibration standard (KC2700KA, Immundiagnostik AG,
Bensheim, Germany) and two controls were measured together with the samples.
EDTA-anticoagulated blood samples from all 56 study subjects were stored at
 80 C and were measured in one batch. After defrosting, the samples were
homogenized on a multiaxle rotating mixer for at least 3 min. Then, 30 ml of the
sample together with 100ml haemolysis solution (96% water and 4% formic acid)
and 1,000 ml acetone were vortexed for 30 s and subsequently centrifuged at
10,000 r.p.m. Fifty microlitres of the supernatant were then injected into the HPLC
system. For calculation of the zinc protoporphyrin/haem ratio, the haemoglobin
concentration was determined from the same aliquots using a Sysmex XE-2100
haematology analyser (Sysmex Corporation, Kobe, Japan) using the SLS
(cyanide-free sodium lauryl sulphate) method.
To minimize intra-assay variations, for each subject, three samples were
prepared according to this protocol and the zinc protoporphyrin and the
protoporphyrin IX concentrations determined. For comparison with the other
methods, the mean values of these triplicate measurements were used. In addition,
inter-assay variations were assessed by measuring aliquots of all 56 subjects
in repeated batches. These batches are compared in a Bland–Altman plot
(see Supplementary Fig. 7).
Clinical evaluation of non-invasive optical measurements. Clinical evaluation
of the non-invasive instrument was carried out in the Perinatal Center, Klinikum
der Universität München, Munich, Germany. A series of studies was conducted in
three phases, with 20 subjects in each of the first two preparatory phases and 56
subjects in the last phase. For participation in the study, exclusion criteria were
(i) transfusion of blood products in the course of delivery, (ii) a diagnosis of
thalassaemia or sickle cell anaemia and (iii) any acute or chronic infectious or
inflammatory disease. Between each phase of the clinical studies, instrumental
improvements were made. We focus here on the results of the last phase, with a
recruitment period from March 2014 to December 2014. For estimation of the CIs
of the limits of agreement between the non-invasive and reference HPLC methods,
the sample size of 56 provided a 95% CI of about ±0.45s, where s is the s.d. of the
differences between measurements by the two methods42. Ethical approval for the
study was given by the Institutional Ethical Board of the Klinikum der Universität
München (study identifier: LFL_01/2012, ClinicalTrials.gov identifier:
NCT02310607). Written informed consent was obtained from each subject.
All non-invasive fluorescence measurements were conducted by the same
physician during the clinically indicated inpatient stay within 3 days after delivery.
For each subject, 10 non-invasive measurements at each of 10 different sites on the
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wet vermillion of the lower lip were performed. The fit amplitudes for the
red blood cell zinc protoporphyrin were averaged for each subject and scaled to the
HPLC value range for comparison. The results were compared with the zinc
protoporphyrin/haem ratio measured by the reference HPLC method from whole
blood for each subject, as described below. After the measurements, study
participants had a medical consultation to discuss the results of the iron deficiency
parameters measured from the blood samples.
Aliquots from residual EDTA-anticoagulated blood samples obtained after
clinically indicated blood withdrawal were anonymized. Two aliquots of 500 ml
each were frozen at  80 C and were used for zinc protoporphyrin determination
by HPLC at the Deutsches Kompetenz-Zentrum für Porphyriediagnostik und
Konsultation, MVZ Labor PD Dr. Volkmann und Kollegen GbR. A 200-ml aliquot
was stored at 8 C for at most 3 days, and used for determination of the red blood
cell zinc protoporphyrin/haem ratio with a commercial haematofluorometer
(Model 206D, AVIV Biomedical Inc., Lakewood, NJ, USA) according to the
manufacturer’s instructions, using materials for calibration and quality control
obtained from the manufacturer.
Statistical data analysis. The zinc protoporphyrin values measured by the
non-invasive fluorescence method yielded arbitrary units. To directly compare
these units with HPLC values, the zinc protoporphyrin values were scaled.
The scaling factor was the slope of a straight line with zero offset fitted to the
comparison of the zinc protoporphyrin values with the mean HPLC values of the
triplicate measurements (software: R version 3.2.0, function: lmrob, package:
robustbase version 0.92-3). Bland–Altman plots show the difference of the scaled
zinc protoporphyrin values and the mean of the HPLC triplicate measurements
against the mean of both values. To compare the two methods, the limits of
agreement and bias shown in the Bland–Altman plots were calculated using a
robust s.d., the robust t-estimate (software: R, function: scaleTau2, package:
robustbase) of the differences between the two methods, multiplied by 1.96. The
95% CIs were calculated by bootstrapping (software: R, functions: boot and boot.ci,
package: boot version 1.3-16). The optimal threshold for the haematofluorometer
measurements was determined by receiver operating characteristic analysis against
classification by HPLC (zinc protoporphyrin 450 mmol per mol haem; software:
R, function: optimal.cutpoints, package: OptimalCutpoints version 1.1-3).
Sensitivity and specificity were calculated from contingency tables (software:
R, function: BDtest, package: bdpv version 1.1).
Monte Carlo simulations. To study the influence of tissue geometry, tissue
optical parameters, as well as the geometry of the fibre-optic probe, Monte Carlo
simulations were performed. These simulations were conducted using a modified
version of a graphic card implementation of the simulation programme ‘Monte
Carlo Multi-Layered’ (MCML)43,44. The modifications include implementation of
fluorescence simulation using the weighted direct emission method45 and
simulation of optical fibres. For this modified MCML programme, photons are
injected at the position of an optical fibre at the tissue surface, equally distributed
across the fibre diameter, while the initial angle of the photon is chosen according
to a cosine distribution but limited by the numerical aperture (NA) of the optical
fibre. For all simulations, the NA of the optical fibres in air was NA¼ 0.22 and
their refraction index nfibre¼ 1.46. The refraction index of the tissue was chosen as
ntissue¼ 1.33. The simulated tissue consists of multiple tissue layers with finite
thickness and infinite extent in the plane. The photons injected by the excitation
fibre propagate through the layers, with each layer having a defined absorption
coefficient ma,exc, scattering coefficient ms,exc and anisotropy parameter gexc for the
Henyey–Greenstein phase function. The fluorescence photons generated are
emitted isotropically and tracked until they leave the tissue, with optical parameters
ma,em, ms,em and gem defined for each layer. Both excitation and fluorescence
photons were cancelled in case their weight became too small by ‘survival roulette’,
while conservation of energy was ensured44–46. The photons detected by one or
more optical fibres, including the excitation fibre, are recorded, summarized and
normalized to the number of excitation photons injected.
The simulated tissue consisted of three layers, the epithelium, the superficial
stroma and the lower stroma. The properties of the superficial and the lower
stroma differed only by the blood content. The optical properties of the epithelium
and the stroma were varied to ensure that the physiological range is covered
(see Supplementary Tables 2 and 3). For Supplementary Fig. 5a, additionally a
blood content of 16% in the lower stroma was simulated. The epithelium thickness
was also varied (50, 100, 200 and 400 mm) for each combination of optical
properties in Supplementary Tables 2 and 3. The superficial stroma was 200-mm
thick, while the thickness of the lower stroma was set to 10 mm. Fluorescence was
generated at the emission wavelengths of 561 and 576 nm (tissue autofluorescence
only) and 593 nm (tissue autofluorescence and zinc protoporphyrin fluorescence).
Zinc protoporphyrin fluorescence was generated only in the blood-perfused
stroma. The amount of fluorescence photons generated was dependent on the
respective absorption coefficient. The contribution of the fluorophores to the
respective absorption coefficient was chosen as 0.1. The quantum efficiency was
chosen as g¼ 1. Fluorescence photons detected by optical fibres were stored
separately for the different tissue layers and fluorophores. In addition, the relative
number of detected excitation photons was recorded. The total number of
excitation photons was 108 for each simulation.
To study the influence of different average blood vessel diameters in the examined
tissue volume, the blood absorption as input parameter for the simulations was
adapted. An average blood vessel diameter of 24mm (s.d.: 14mm) was found by
Amelink et al. for normal oral mucosa47. Therefore, in addition to evenly distributed
erythrocytes, blood vessel diameters of 24, 38 and 52mm were simulated to cover the
physiological range. Larger blood vessels reduced the blood absorption, especially at
wavelengths with high blood absorption according to the formula described by van
Veen et al.48. The resulting absorption coefficient of 1% blood at 425 nm was then
0.413, 0.263 and 0.192 mm 1 for 24, 38 and 52mm vessel diameters, respectively; at
561 nm it was 0.153, 0.136 and 0.121 mm 1; at 576 nm it was 0.206, 0.174 and
0.148 mm 1; and at 593 nm it was 0.056, 0.054 and 0.052 mm 1.
The absorption caused by blood at its absorption maximum around 576 nm, the
blood absorption index, was quantified by using the autofluorescence detected at
561 and 576 nm. Both detected autofluorescence signals were divided by emaa ,
with ma the respective blood absorption coefficient (Supplementary Fig. 3), where
the blood absorption index a was varied such that the result was equal for both
wavelengths.
To study the influence of the fibre diameter, separate simulations with optical
fibres with diameters 200, 400, 600, 800, 1,000 and 1,500 mm were performed,
with the fibres embedded in a perfectly reflecting 12-mm ferrule. For the other
simulations, the fibre-optic probe shown in Supplementary Fig. 2b was simulated.
For comparison with the fluorescence detected from a whole-blood sample, the
following Monte Carlo simulation was performed. The fibre-optic probe was in
contact with a 1-cm-thick whole-blood sample. The blood was assumed to contain
96% oxygenized and 4% deoxygenized haemoglobin. Packaging was not considered
because of the high absorber concentration. The absorption of the sample
was therefore 188.49 mm 1 (excitation wavelength, 425 nm) and 4.79 mm 1
(fluorescence wavelength, 593 nm), respectively. Scattering of the whole-blood
sample was disregarded.
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